CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – ...

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Colossal Biosciences wants to bring back the woolly mammoth and has raised $200 million at a $10.2 billion valuation to do it ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...

To prepare students for the challenges and opportunities of an increasingly AI-driven world, Connecticut College has launched ...

The colder months have become synonymous with an uptick in respiratory illnesses like the flu and RSV and this winter is no ...

The Cambridge Police Department said they responded to a crash on Clarendon Avenue involving two cars and property damage, ...

Healthtech startup ErlySign has raised Rs 16 crore ($1.8 million) in its pre-Series A round from Ashish Kacholia. Snippets ...